Get the Stockscreener App
440.06
0.01%
0.06
After Hours:
440.06
United Therapeutics Corp stock is traded at $440.06, with a volume of 378.29K.
It is up +0.01% in the last 24 hours and up +8.65% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$440.00
Open:
$437.53
24h Volume:
378.29K
Relative Volume:
0.51
Market Cap:
$19.85B
Revenue:
$3.08B
Net Income/Loss:
$1.24B
P/E Ratio:
17.18
EPS:
25.6108
Net Cash Flow:
$1.07B
1W Performance:
-2.92%
1M Performance:
+8.65%
6M Performance:
+56.52%
1Y Performance:
+22.85%
1-Day Range:
$430.89
$443.11
1-Week Range:
$430.89
$459.48
52-Week Range:
$266.98
$459.48
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
440.06 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
142.26 | 62.54B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 43.30B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.08 | 40.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.02 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
Callan Family Office LLC Increases Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Inspire Investing LLC Trims Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics Corp. Hits New 52-Week High of $455.26 - Markets Mojo
United Therapeutics Corp. Hits New 52-Week High of $459.48 - Markets Mojo
United Therapeutics Corp. Hits New 52-Week High of $455.00 - Markets Mojo
United Therapeutics (NASDAQ:UTHR) Sets New 52-Week HighHere's What Happened - MarketBeat
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
QRG Capital Management Inc. Raises Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Is There Still an Opportunity in United Therapeutics After Its 25.8% Year to Date Surge? - simplywall.st
Polaris Capital Management LLC Reduces Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Hilltop National Bank Takes $341,000 Position in United Therapeutics Corporation $UTHR - MarketBeat
A Look at United Therapeutics (UTHR) Valuation as Tyvaso Shows Breakthrough Results in Late-Stage IPF Trial - simplywall.st
How Positive TETON-2 Results for Tyvaso Have Changed United Therapeutics' (UTHR) Investment Story - simplywall.st
News impact scoring models applied to United Therapeutics CorporationPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Robeco Institutional Asset Management B.V. Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
Lecap Asset Management Ltd. Takes $667,000 Position in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics stock hits all-time high at 442.02 USD - Investing.com
United Therapeutics stock hits all-time high at 442.02 USD By Investing.com - Investing.com South Africa
United Therapeutics rides Tyvaso optimism as IPF trial gains momentum - S&P Global
TD Cowen maintains Buy rating on United Therapeutics stock, citing IPF opportunity - Investing.com
Jefferies reiterates Buy rating on United Therapeutics stock amid patent case - Investing.com
UBS maintains United Therapeutics stock Buy rating amid patent litigation By Investing.com - Investing.com Canada
United Therapeutics COO sells $9.49m in UTHR stock By Investing.com - Investing.com South Africa
United Therapeutics COO sells $9.49m in UTHR stock - Investing.com India
Is IPF the Next Big Market Opportunity for United Therapeutics? - Yahoo Finance
UBS maintains United Therapeutics stock Buy rating amid patent litigation - Investing.com India
United Therapeutics president Michael Benkowitz sells shares worth $3.65m - MSN
United Therapeutics stock price target raised to $580 by UBS on Tyvaso outlook - Investing.com Australia
United Therapeutics Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
United Therapeutics stock maintains Buy rating at H.C. Wainwright amid patent case developments - Investing.com Australia
United Therapeutics (UTHR): UBS Raises Price Target to $580, Mai - GuruFocus
United Therapeutics stock maintains Buy rating at H.C. Wainwright amid patent case developments By Investing.com - Investing.com Australia
Will United Therapeutics Corporation (UTH) stock beat international competitionWeekly Trade Review & Reliable Trade Execution Plans - newser.com
United Therapeutics stock holds Buy rating at TD Cowen on strong IPF data - Investing.com Canada
United Therapeutics stock holds Buy rating at TD Cowen on strong IPF data By Investing.com - Investing.com South Africa
United Therapeutics Corporation $UTHR Holdings Lifted by State of Alaska Department of Revenue - MarketBeat
Why United Therapeutics Corporation (UTH) stock stays undervaluedTrade Ideas & Verified Chart Pattern Trade Signals - newser.com
Analyzing drawdowns of United Therapeutics Corporation with statistical tools2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - newser.com
Why United Therapeutics Corporation (UTH) stock gets analyst attention2025 Winners & Losers & Low Risk Investment Opportunities - newser.com
Chart based analysis of United Therapeutics Corporation trendsInsider Selling & Real-Time Stock Movement Alerts - newser.com
Augustine Asset Management Inc. Makes New Investment in United Therapeutics Corporation $UTHR - MarketBeat
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Zai Lab (ZLAB) - The Globe and Mail
United Therapeutics Rides Tyvaso Wins To Major Gains - Finimize
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 10 '25 |
Option Exercise |
120.26 |
4,000 |
481,040 |
4,130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 09 '25 |
Sale |
448.91 |
4,000 |
1,795,655 |
130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 10 '25 |
Sale |
444.70 |
4,000 |
1,778,788 |
130 |
0.05%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):